Cargando…

Therapie von Komplikationen und nichtpharmakologisches Management der idiopathischen pulmonalen Fibrose

Complications of idiopathic pulmonary fibrosis (IPF) are responsible for a relevant proportion of the mortality. Most importantly, acute exacerbation leads to an in-hospital mortality of more than 50% with a mean survival time of only a few months. Therefore, consideration of complications in IPF is...

Descripción completa

Detalles Bibliográficos
Autores principales: Gläser, S., Glöckl, R., Bonella, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087706/
https://www.ncbi.nlm.nih.gov/pubmed/32206051
http://dx.doi.org/10.1007/s10405-020-00313-w
_version_ 1783509386749018112
author Gläser, S.
Glöckl, R.
Bonella, F.
author_facet Gläser, S.
Glöckl, R.
Bonella, F.
author_sort Gläser, S.
collection PubMed
description Complications of idiopathic pulmonary fibrosis (IPF) are responsible for a relevant proportion of the mortality. Most importantly, acute exacerbation leads to an in-hospital mortality of more than 50% with a mean survival time of only a few months. Therefore, consideration of complications in IPF is of great importance for understanding the disease and treatment planning. Furthermore, the evidence for pneumological rehabilitation in IPF has greatly increased. This resulted in specific recommendations by the American Thoracic Society (ATS) and the European Respiratory Society (ERS) for improvement in physical capacity, quality of life and symptom control.
format Online
Article
Text
id pubmed-7087706
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Medizin
record_format MEDLINE/PubMed
spelling pubmed-70877062020-03-23 Therapie von Komplikationen und nichtpharmakologisches Management der idiopathischen pulmonalen Fibrose Gläser, S. Glöckl, R. Bonella, F. Pneumologe (Berl) Leitthema Complications of idiopathic pulmonary fibrosis (IPF) are responsible for a relevant proportion of the mortality. Most importantly, acute exacerbation leads to an in-hospital mortality of more than 50% with a mean survival time of only a few months. Therefore, consideration of complications in IPF is of great importance for understanding the disease and treatment planning. Furthermore, the evidence for pneumological rehabilitation in IPF has greatly increased. This resulted in specific recommendations by the American Thoracic Society (ATS) and the European Respiratory Society (ERS) for improvement in physical capacity, quality of life and symptom control. Springer Medizin 2020-03-23 2020 /pmc/articles/PMC7087706/ /pubmed/32206051 http://dx.doi.org/10.1007/s10405-020-00313-w Text en © Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Leitthema
Gläser, S.
Glöckl, R.
Bonella, F.
Therapie von Komplikationen und nichtpharmakologisches Management der idiopathischen pulmonalen Fibrose
title Therapie von Komplikationen und nichtpharmakologisches Management der idiopathischen pulmonalen Fibrose
title_full Therapie von Komplikationen und nichtpharmakologisches Management der idiopathischen pulmonalen Fibrose
title_fullStr Therapie von Komplikationen und nichtpharmakologisches Management der idiopathischen pulmonalen Fibrose
title_full_unstemmed Therapie von Komplikationen und nichtpharmakologisches Management der idiopathischen pulmonalen Fibrose
title_short Therapie von Komplikationen und nichtpharmakologisches Management der idiopathischen pulmonalen Fibrose
title_sort therapie von komplikationen und nichtpharmakologisches management der idiopathischen pulmonalen fibrose
topic Leitthema
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087706/
https://www.ncbi.nlm.nih.gov/pubmed/32206051
http://dx.doi.org/10.1007/s10405-020-00313-w
work_keys_str_mv AT glasers therapievonkomplikationenundnichtpharmakologischesmanagementderidiopathischenpulmonalenfibrose
AT glocklr therapievonkomplikationenundnichtpharmakologischesmanagementderidiopathischenpulmonalenfibrose
AT bonellaf therapievonkomplikationenundnichtpharmakologischesmanagementderidiopathischenpulmonalenfibrose